Literature DB >> 28439946

Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension.

Tiffany Tsai1, Miranda E Kroehl2, Steven M Smith3, Angela M Thompson1, Isabella Y Dai1, Katy E Trinkley1,4.   

Abstract

This retrospective cohort study compared administration of lisinopril twice daily and once daily for hypertension. Data were collected from an ambulatory electronic health record between 2011 and 2014. Patients previously receiving lisinopril 20 mg were placed into the once-daily cohort if changed to 40 mg once daily or into the twice-daily cohort if changed to 20 mg twice daily. Efficacy outcome measures were change in systolic blood pressure and diastolic blood pressure and achievement of blood pressure control (<140/90 mm Hg). Of 90 patients included (45 per cohort), the mean age was 61.8 years and 17.8% were black. Once- and twice-daily administrations were associated with blood pressure reductions of 6.2/1.5 mm Hg and 16.5/5.9 mm Hg, with a 10.2/4.3 mm Hg greater reduction with twice-daily administration (systolic blood pressure, P=.016; diastolic blood pressure, P=.068). Twice-daily lisinopril dosing was associated with greater systolic blood pressure reductions compared with the same total daily dose administered once daily. ©2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28439946      PMCID: PMC8031210          DOI: 10.1111/jch.13011

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  16 in total

1.  Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.

Authors:  A C Schoolwerth; D A Sica; B J Ballermann; C S Wilcox
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension.

Authors:  N Martell; B Gill; R Marin; C Suarez; J L Tovar; P Cia; C Fernandez; L Gonzalez; A Maldonado; F Fernández; C del Arco; I Garcia; I Yuste; M Luque
Journal:  J Hum Hypertens       Date:  1998-01       Impact factor: 3.012

3.  Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010.

Authors:  Qiuping Gu; Vicki L Burt; Charles F Dillon; Sarah Yoon
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

Review 4.  Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.

Authors:  C M White
Journal:  Pharmacotherapy       Date:  1998 May-Jun       Impact factor: 4.705

5.  Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.

Authors:  R Copher; P Buzinec; V Zarotsky; L Kazis; S U Iqbal; D Macarios
Journal:  Curr Med Res Opin       Date:  2010-04       Impact factor: 2.580

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Hypertension treatment in a medicare population: adherence and systolic blood pressure control.

Authors:  Vicki Fung; Jie Huang; Richard Brand; Joseph P Newhouse; John Hsu
Journal:  Clin Ther       Date:  2007-05       Impact factor: 3.393

8.  Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?

Authors:  Khedidja Hedna; Katja M Hakkarainen; Hanna Gyllensten; Anna K Jönsson; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

9.  Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension.

Authors:  Tiffany Tsai; Miranda E Kroehl; Steven M Smith; Angela M Thompson; Isabella Y Dai; Katy E Trinkley
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-04-25       Impact factor: 3.738

10.  Comparative efficacy of two different beta-blockers on 24-hour blood pressure control.

Authors:  Pantelis Sarafidis; Zvezdana Bogojevic; Emad Basta; Emily Kirstner; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

View more
  2 in total

1.  Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.

Authors:  Catherine G Derington; Jordan B King; Thomas Delate; Sheila R Botts; Miranda Kroehl; David P Kao; Katy E Trinkley
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

2.  Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension.

Authors:  Tiffany Tsai; Miranda E Kroehl; Steven M Smith; Angela M Thompson; Isabella Y Dai; Katy E Trinkley
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-04-25       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.